The NIDDK established a multi-center Drug Induced Liver Injury Network (DILIN) in order to develop standardized instruments to identify and fully characterize cases of drug-induced liver injury; define the epidemiology and clinical spectrum of drug-induced liver injury; and obtain biological samples for study of the pathogenesis of drug-induced liver injury using the most current biochemical, serological and genetic techniques. Support from the private sector through the FNIH enabled the NIDDK to expand and broaden the Network’s goals.